MAH/QP/QPPV Requirements

Maximize your Regulatory compliance in Europe with Freyr's expert MAH services. Our tailored approach covers pharmacovigilance, market authorization procedures, and legal representation, ensuring seamless operations for medicinal product manufacturers.

MAH/QP/QPPV Requirements - Overview

European manufacturers and Marketing Authorization Holders (MAHs) of medicinal products have various responsibilities. For example, to execute the batch release process and to perform the legal requirements related to Pharmacovigilance, MAHs must identify suitable individuals to perform the roles of Qualified Person (QP) and Qualified Person responsible for Pharmacovigilance (QPPV).

Many other activities undertaken by the MAHs require the support of a QP to meet the requirements of Health Authorities (HAs) throughout the European region. For example, the advice of a QP can be valuable in mergers or acquisitions to ensure all relevant quality aspects are considered.

The QPPV acts as a single point of contact for HAs for product safety-related topics. The responsibilities include establishing and maintaining the Pharmacovigilance system, ensuring the safety profiles of the company’s medicinal products are kept up-to-date, and meeting legal obligations on the reporting of safety concerns. As part of the Pharmacovigilance system, the MAH shall have an appropriate Qualified Person (QP) responsible for Pharmacovigilance in the EU (EU QPPV) [DIR Art 104(3)(a)], at its disposal. The MAH shall submit the name and contact details of the QPPV to the competent authorities in the Member States and the Agency [DIR Art 104(3) last paragraph]. Changes to this information should be submitted per Regulation (EC) No 1234/2008 on variations to the terms of the marketing authorization.

In addition to the QPPV, competent authorities in the member states are legally provided with the option to request the nomination of a Pharmacovigilance contact person at the national level who reports to the QPPV. Reporting, in this context, relates to Pharmacovigilance tasks and responsibilities and not necessarily to line management. A contact person at the national level may also be nominated as the QPPV. Overall, the MAH should ensure that structures and processes are in place so the QPPV can fulfill its responsibilities. In the UK, companies need to make sure that they meet specific obligations that will apply to the provisions of QPPV services following the end of the Brexit transition period.

Freyr, through its comprehensive resources, can provide end-to-end MAH services and act as a local representative and can assist in providing QPPV services along with end-to-end Regulatory strategic consulting.

MAH/QP/QPPV Requirements - Expertise

  • Single point of contact for QPPV, adverse event reporting, signal detection & evaluation, and other Pharmacovigilance services.
  • Support in the appointment of a Qualified Person (QP), Qualified Person responsible for Pharmacovigilance (QPPV), and National Person for Pharmacovigilance (NPPV) in all the EU countries.
  • Track safety variations and PV system master file compliance.
  • Brexit-related Regulatory support, including assistance with market entry for companies without an approved product in the EEA or UK, QP changes, Pharmacovigilance System Master File (PSMF), EU QPPV requirements, etc.
  • Market authorization procedures (i.e., Centralized, MRP, DCP, and National)
  • Acquiring submission slots from HA.
  • Compilation, review, and submission of Market Authorization Application (MAA) - Article 10(1).
  • Legal representation as Marketing Authorization Holders (MAHs) for medicinal product manufacturers without establishments in the European Economic Area (EEA).
  • Regulatory experts with a comprehensive understanding of HA requirements.
  • Lifecycle management of medicinal products, including MA license renewal.
MAH/QP/QPPV Requirements

Celebrating Customers Success

 

Medicinal Products

Regulatory Affairs

India

Thank you for the timely support over the weekend, which allowed us to resubmit quickly after being notified. This continuously demonstrates Freyr's commitment towards our company’s milestones.

Director - Global Regulatory Affairs – Operations

India-based, Global Top Generic Pharma Company

 

Medicinal Products

Publishing

UK

I am sure you have heard by now that we have received our first-ever approval from the FDA for our Brands division. This is a major milestone for us as well as for my team here in Reg Ops. I would be remiss if I didn’t point out that we would not have been able to do this without the help of your dedicated team. From the original filing, then the following year of responses, all helped get us to final approval.

Thank you Freyr team for a job well done!

Sr. Director, Head of Regulatory Operations

Ireland-based, Global Specialty Pharmaceutical Company

 

Medicinal Products

Regulatory Affairs

USA

Please relate to the team the excellent job they have done on the IND reactivation. Specifically, the high-quality module 3, written by Freyr. It was very comprehensive, very few revisions were required, and we had no questions from Health Canada or FDA. No CMC questions: that was a first for me. So very responsive to my many requests, which I am sure can be frustrating but always helpful while producing excellent work.

Thank you for always being available and responding quickly and comprehensively to all my requests.

What a great team you have, Freyr.

Lynne McGrath

Regulatory Consultant

 

Medicinal Products

Regulatory Affairs

USA

Congratulations!!! ​

Thanks for your great support for a successful ANDA filing, especially to the publishing team. Heartfully appreciate their last hours of hard work.

Assistant Manager​

US-based, Leading, Complex Generic Pharmaceutical Products Company​

 

Medicinal Products

Regulatory Affairs

USA

Thank you all for the great support!​

CEO

US-based, Leading Innovative Pharmaceuticals Company​

 

Medicinal Products

Regulatory Affairs

USA

The ANDA receipt has been received! Thank you very much for your hard work, patience, and support for our work over the last couple of months. We are delighted that we were able to meet the timeline and hit an important corporate goal of our young company. ​

Thank you again, and we look forward to working with your team on the next project!

Senior Director of Business and Product Development​

US-based, Leading Innovator Pharmaceuticals Company​